03/06/2017 - Valeant Pharmaceuticals International, Inc. had its "neutral" rating reiterated by analysts at Rodman & Renshaw. The last session's volume of 12.32 million shares was lower than its average volume of 19.66 million shares.
Valeant Pharmaceuticals Intl (NYSE:VRX) opened at 8.88 on Monday.
Several other equities analysts have also recently issued reports on VRX.
Valeant Pharmaceuticals International, Inc. had its "hold" rating reiterated by analysts at Deutsche Bank. TD Securities reissued a hold rating and set a C$18.50 price target on shares of Valeant Pharmaceuticals Intl in a research report on Friday, February 17th.
The stock subtracted in the prior trading session by -1.55%, closing at the stock price of $8.88. The current share price indicate that stock is -25.00% away from its one year high and is moving 2.82% ahead of its 52-week low. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and six have given a buy rating to the company's stock.
The number of shares now held by investors is 347.85 Million. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Ross acquired 5,000 shares of the stock in a transaction on Wednesday, December 14th. The shares were purchased at an average price of $10.80 per share, for a total transaction of $108,000.00. 8,109,907 shares of the company were exchanged. The disclosure for this sale can be found here. The company has grown 16.90% in past 3 months and in the last five trades has moved up 1.73%. Morgan Stanley boosted its position in Valeant Pharmaceuticals Intl by 241.6% in the third quarter. Renaissance Technologies LLC now owns 2,913,089 shares of the specialty pharmaceutical company's stock worth $42,294,000 after buying an additional 2,480,600 shares during the last quarter. Private Advisor Group LLC now owns 11,765 shares of the specialty pharmaceutical company's stock valued at $180,000 after buying an additional 2,213 shares in the last quarter. Shares are trading 4.20% above their 50-day moving average, and 11.03% below their 200-day moving average. (VRX) is 3.09 Billion. Stock traders acquired 1,451 put options on the stock. This represents an increase of 123% compared to the typical volume of 652 put options. The specialty pharmaceutical company reported $1.26 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.20 by $0.06. The firm had revenue of $2.40 billion for the quarter, compared to analysts' expectations of $2.34 billion. Valeant Pharmaceuticals Intl had a positive return on equity of 43.81% and a negative net margin of 22.17%. The stock has earnings growth of -1.60% yoy and showed a high EPS growth of 6.70% over the past five years.